Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
8.59
-0.20 (-2.28%)
At close: Oct 21, 2025, 4:00 PM EDT
8.60
+0.01 (0.12%)
After-hours: Oct 21, 2025, 7:59 PM EDT
Novavax Revenue
Novavax had revenue of $239.24M in the quarter ending June 30, 2025, a decrease of -42.42%. This brings the company's revenue in the last twelve months to $1.08B, up 9.22% year-over-year. In the year 2024, Novavax had annual revenue of $682.16M, down -30.65%.
Revenue (ttm)
$1.08B
Revenue Growth
+9.22%
P/S Ratio
1.28
Revenue / Employee
$1,133,107
Employees
952
Market Cap
1.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NVAX News
- 7 days ago - Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Benzinga
- 7 days ago - Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps - Reuters
- 14 days ago - Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment - PRNewsWire
- 21 days ago - Novavax Announces Progress on Sanofi Agreement - PRNewsWire
- 6 weeks ago - Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 weeks ago - Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment - PRNewsWire
- 6 weeks ago - Novavax to Participate in the Cantor Global Healthcare Conference - PRNewsWire
- 7 weeks ago - Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. - PRNewsWire